Epilepsy, a chronic neurological disorder, is characterized by recurrent seizures affecting people of all ages. Despite the availability of numerous anti-epileptic drugs (AEDs), a significant proportion of patients continue to experience uncontrolled seizures. This necessitates a continuous pursuit of advancements in the management of epilepsy.
Recent years have witnessed the introduction of new generation AEDs with unique mechanisms of action. These include Brivaracetam, Perampanel, and Lacosamide, which have shown promising results in terms of efficacy and tolerability. These drugs target novel pathways, thus expanding treatment options for refractory epilepsy.
Neuromodulation techniques such as Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Responsive Neurostimulation (RNS) have emerged as effective treatment strategies. These interventions modulate neuronal activity, reducing seizure frequency and severity. While invasive, their use is justified in drug-resistant cases.
With the advent of next-generation sequencing, genetic testing has become increasingly relevant in epilepsy management. Identification of specific genetic mutations can guide the choice of AEDs, paving the way for precision medicine in epilepsy.
The COVID-19 pandemic has accelerated the adoption of telemedicine in epilepsy care. Virtual consultations, remote monitoring of seizure activity, and online delivery of cognitive behavioral therapy have proven effective and convenient for patients, particularly those residing in remote areas.
Advancements in epilepsy management, from novel AEDs to neuromodulation techniques, genetic testing, and telemedicine, have significantly improved patient outcomes. As we continue to explore these frontiers, it is crucial for healthcare professionals to stay updated and adapt to these changes, ensuring optimal care for patients with epilepsy.
1.
Regular physical activity before cancer diagnosis may lower progression and death risks
2.
Medication Self-Injection Embraced by Breast Cancer Patients
3.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
4.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
5.
ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs
1.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
2.
Clinical Pathways in Hematology in Clinical Decision-Making
3.
Immune Surveillance Screening for Early Cancer Risk Detection
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
AI-Driven Digital Pathology in Oncology: From Histology Images to Predictive Treatment Biomarkers
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Signs and Symptoms of Leukemia
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation